Biosimilar arthritis drug shows Real-World safety data
NCT ID NCT03885037
First seen Jan 09, 2026 · Last updated May 10, 2026 · Updated 13 times
Summary
This study looked at how safe and effective Infliximab BS (a biosimilar of Remicade) is for people with rheumatoid arthritis in everyday medical practice. 77 adults who were starting this drug for the first time took part. Researchers tracked side effects and measured changes in disease activity using joint counts and blood tests. The goal was to gather real-world information, not to test a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Local Country Office
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.